[TENAGA] YoY Cumulative Quarter Result on 31-May-2017 [#3]

Stock
[TENAGA] TENAGA NASIONAL BHD
Announcement Date
27-Jul-2017
Admission Sponsor
-
Sponsor
-
Financial Year
31-Aug-2017
Quarter
31-May-2017 [#3]
Profit Trend
QoQ--%
YoY- -7.5%
Quarter Report
Latest QR
Upcoming QR
TENAGA's Result
TENAGA's Financial Summary
View:
Show?
Cumulative Result
30/09/19 30/09/18 30/09/17 31/05/17 31/05/16 31/05/15 31/05/14 CAGR
Revenue 38,762,600 37,845,700 0 34,953,100 33,294,800 31,542,800 31,069,000 4.23%
PBT 4,702,900 4,843,900 0 6,129,400 6,194,500 5,721,200 4,804,900 -0.40%
Tax -842,000 -947,300 0 -951,800 -610,100 -469,900 299,900 -
NP 3,860,900 3,896,600 0 5,177,600 5,584,400 5,251,300 5,104,800 -5.09%
-
NP to SH 3,875,900 3,858,000 0 5,184,800 5,605,400 5,297,500 5,111,100 -5.05%
-
Tax Rate 17.90% 19.56% - 15.53% 9.85% 8.21% -6.24% -
Total Cost 34,901,700 33,949,100 0 29,775,500 27,710,400 26,291,500 25,964,200 5.69%
-
Net Worth 57,382,980 57,861,523 0 55,356,592 51,081,829 46,728,270 33,862,533 10.38%
Dividend
30/09/19 30/09/18 30/09/17 31/05/17 31/05/16 31/05/15 31/05/14 CAGR
Div 1,706,066 1,717,176 - 962,034 564,377 564,344 564,375 23.03%
Div Payout % 44.02% 44.51% - 18.55% 10.07% 10.65% 11.04% -
Equity
30/09/19 30/09/18 30/09/17 31/05/17 31/05/16 31/05/15 31/05/14 CAGR
Net Worth 57,382,980 57,861,523 0 55,356,592 51,081,829 46,728,270 33,862,533 10.38%
NOSH 5,686,888 5,678,180 5,659,016 5,659,026 5,643,777 5,643,442 5,643,755 0.14%
Ratio Analysis
30/09/19 30/09/18 30/09/17 31/05/17 31/05/16 31/05/15 31/05/14 CAGR
NP Margin 9.96% 10.30% 0.00% 14.81% 16.77% 16.65% 16.43% -
ROE 6.75% 6.67% 0.00% 9.37% 10.97% 11.34% 15.09% -
Per Share
30/09/19 30/09/18 30/09/17 31/05/17 31/05/16 31/05/15 31/05/14 CAGR
RPS 681.61 667.14 0.00 617.65 589.94 558.93 550.50 4.08%
EPS 68.16 68.01 0.00 91.62 99.32 93.87 90.56 -5.18%
DPS 30.00 30.27 0.00 17.00 10.00 10.00 10.00 22.85%
NAPS 10.0904 10.1997 0.00 9.782 9.051 8.2801 6.00 10.23%
Adjusted Per Share Value based on latest NOSH - 5,658,592
30/09/19 30/09/18 30/09/17 31/05/17 31/05/16 31/05/15 31/05/14 CAGR
RPS 668.68 652.86 0.00 602.96 574.35 544.13 535.96 4.23%
EPS 66.86 66.55 0.00 89.44 96.70 91.38 88.17 -5.05%
DPS 29.43 29.62 0.00 16.60 9.74 9.74 9.74 23.02%
NAPS 9.8989 9.9814 0.00 9.5493 8.8119 8.0609 5.8415 10.38%
Price Multiplier on Financial Quarter End Date
30/09/19 30/09/18 30/09/17 31/05/17 31/05/16 31/05/15 31/05/14 CAGR
Date 30/09/19 28/09/18 29/09/17 31/05/17 31/05/16 29/05/15 30/05/14 -
Price 13.64 15.46 14.32 13.78 13.98 13.36 12.06 -
P/RPS 2.00 2.32 0.00 2.23 2.37 2.39 2.19 -1.68%
P/EPS 20.01 22.73 0.00 15.04 14.08 14.23 13.32 7.92%
EY 5.00 4.40 0.00 6.65 7.10 7.03 7.51 -7.33%
DY 2.20 1.96 0.00 1.23 0.72 0.75 0.83 20.03%
P/NAPS 1.35 1.52 0.00 1.41 1.54 1.61 2.01 -7.18%
Price Multiplier on Announcement Date
30/09/19 30/09/18 30/09/17 31/05/17 31/05/16 31/05/15 31/05/14 CAGR
Date 27/11/19 27/11/18 - 27/07/17 28/07/16 30/07/15 16/07/14 -
Price 13.56 14.72 0.00 14.24 14.32 12.12 12.46 -
P/RPS 1.99 2.21 0.00 2.31 2.43 2.17 2.26 -2.35%
P/EPS 19.90 21.64 0.00 15.54 14.42 12.91 13.76 7.15%
EY 5.03 4.62 0.00 6.43 6.94 7.75 7.27 -6.66%
DY 2.21 2.06 0.00 1.19 0.70 0.83 0.80 20.97%
P/NAPS 1.34 1.44 0.00 1.46 1.58 1.46 2.08 -7.90%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment